Zahra Golestani Hotkani
1 
, Tella Sadighpour
2 , Ali Shirbacheh
3 , Kamran Shirbache
4* 1 Department of Bioscience, University of Milan, Milan, Italy.
2 Resident Physician at NH Dartmouth Family Medicine Residency (NHDFMR), Concord Hospital, New Hampshire, USA.
3 Urgences, Centre Hospitalier de l’Agglomération de Nevers, Nevers, France.
4 Hôpital Robert Debré, Groupe Hospitalier Universitaire AP-HP Nord-Université Paris-Cité, France.
Abstract
Several observational studies have indicated a potential protective effect of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) against lung cancer. These investigations have demonstrated a reduced risk of lung cancer among individuals utilizing ACEIs or ARBs compared to those not receiving these medications. However, it is crucial to acknowledge that observational studies cannot establish a cause-and-effect relationship, as other confounding factors may be at play. Conversely, conflicting outcomes have been reported in certain studies, revealing no discernible association between ACEIs/ARBs and the risk of lung cancer. Furthermore, limited evidence from randomized controlled trials specifically designed to investigate this relationship exists. It is imperative to recognize that these trials have inherent limitations, including potential biases and confounding factors. Therefore, additional research is essential to ascertain a definitive connection between ACEIs/ARBs and lung cancer. This review seeks to assess the available data and explore potential mechanisms underlying this association.